INTRODUCTION
============

Standard chemotherapy for tuberculosis (TB) is highly effective, but a long duration of treatment and multiple drugs may be required. Therefore, adverse drug reactions (ADRs) during anti-TB treatment are common and can limit their use \[[@b1-kjim-2018-063],[@b2-kjim-2018-063]\]. Importantly, ADRs can lead to discontinuation of anti-TB treatment and worse outcomes \[[@b3-kjim-2018-063]\]. Cutaneous adverse drug reactions (CADRs) are among the most common ADRs and a common cause of discontinuation of anti-TB drugs \[[@b4-kjim-2018-063]\]. They can cause reactions that range from a mild presentation with pruritus and a skin rash to fatal and life-threatening hypersensitivity reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and the drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome \[[@b1-kjim-2018-063],[@b5-kjim-2018-063]-[@b13-kjim-2018-063]\].

Hypersensitivity reactions can be accompanied by peripheral blood eosinophilia \[[@b14-kjim-2018-063],[@b15-kjim-2018-063]\]. Antibiotics are an important cause of eosinophilia, and patients with eosinophilia have a higher risk of skin rash \[[@b16-kjim-2018-063]\]. However, limited information is available regarding peripheral blood eosinophilia during anti-TB treatment. We aimed to evaluate the prevalence and clinical significance of peripheral blood eosinophilia in patients undergoing anti-TB treatment.

METHODS
=======

Patients and data collection
----------------------------

We retrospectively reviewed the data of all patients who received treatment for active TB at the Chonnam National University Hospital between January 2010 and December 2014. Patients with peripheral blood eosinophilia during anti-TB treatment were included in this study. Patients transferred to another institution before treatment completion, those with peripheral blood eosinophilia before anti-TB treatment, those lost to follow-up, and those started on anti-TB drugs in other hospitals were excluded.

TB was diagnosed based on Mycobacterium tuberculosis identification with culture or polymerase chain reaction from clinical specimens, or on clinical, radiological, or histological findings compatible with TB and responses to anti-TB treatment. In Korea, a 6-month regimen consisting of a 2-month initial phase of isoniazid, rifampicin, pyrazinamide, and ethambutol, followed by a 4-month continuation phase of isoniazid, rifampicin, and ethambutol has been recommended by the National Tuberculosis Program \[[@b17-kjim-2018-063]\]. Alternatively, a 9-month regimen with isoniazid, rifampin, and ethambutol can be administered. Therefore, all patients in this study received daily therapy consisting of isoniazid (300 mg), rifampin (450 to 600 mg), and ethambutol (800 to 1,200 mg), with or without pyrazinamide (1,500 mg). However, the decision to include pyrazinamide in the initial regimen was made by clinicians based on each patient's clinical situation. All patients with TB in our hospital were registered in a TB registry and received health education as well as monitoring for drug compliance and ADRs during treatment by specially trained nurses who participate in the Public-Private Mix project for TB control in Korea \[[@b18-kjim-2018-063]\]. Anti-TB drugs were self-administered with the support of trained nurses. At each clinic visit, treatment adherence was assessed by asking patients about drug intake and checking the tablets remaining from the previously prescribed regimen. In our hospital, all patients with TB underwent laboratory examinations, including complete blood cell count, liver function tests, renal function tests, and C-reactive protein, before treatment and at every hospital visit, which was scheduled every 1 to 2 months during treatment; if patients had symptoms related to ADRs, including fatigue, rash, and fever, additional laboratory examinations were performed.

The protocol of this retrospective observational study was approved by the Chonnam National University Hospital Institutional Review Board, and the requirement for informed consent was waived because of the retrospective nature of this study (IRB number, CNUH 2018-160).

Eosinophilia and adverse drug reactions
---------------------------------------

Eosinophilia was defined as blood eosinophil count above 5% of total white blood cell count \[[@b19-kjim-2018-063]\]. During a period of eosinophilia, initial peripheral counts and percentages, defined as eosinophil counts and percentages at first detection of eosinophilia, and peak eosinophil counts and percentages, defined as the highest eosinophil counts and percentages, were analyzed to evaluate the differences between patients with and without CADRs.

CADRs were defined as newly developed skin reactions including pruritus, skin rash, DRESS, and SJS/TEN during anti-TB treatment that were accompanied by peripheral blood eosinophilia. SJS/TEN was defined as epidermal detachment and mucous membrane erosion \[[@b20-kjim-2018-063]\]. Patients with CADRs were divided into four groups based on the severity of CADRs. Group 1 had no CADRs, group 2 had itching without skin rash, group 3 had skin rash with or without itching, and group 4 had DRESS syndrome, SJS/TEN, and an uncontrolled skin rash and/or fever requiring discontinuation of anti-TB drugs.

Abnormal liver function was defined as elevated serum aminotransferase levels more than two times the upper normal limit that were accompanied by peripheral blood eosinophilia \[[@b21-kjim-2018-063]\]. Abnormal renal function was defined as elevated serum creatinine levels more than 1.5 times baseline that were accompanied by peripheral blood eosinophilia \[[@b22-kjim-2018-063]\].

An offending drug was identified when symptoms and signs resolved after drug withdrawal and recurred after rechallenge with that drug.

Statistical analysis
--------------------

All data are expressed as medians and interquartile range (IQR) or as numbers (percentages) in the text and tables. Intergroup comparisons were performed using the Mann-Whitney *U* test for continuous variables, and Pearson's chi-square test or Fisher's exact test for categorical variables. We evaluated trends using the Jonckheere-Terpstra test. Bonferroni tests were used for post hoc correction to account for multiple comparisons. Variables that were statistically significant in univariate analysis were included in multivariable binary logistic regression analysis to determine predictors for CADRs. The level of significance was set at *p* \< 0.05. Data were analyzed using SPSS for Windows version 22.0 (IBM Co., Armonk, NY, USA).

RESULTS
=======

Patient characteristics
-----------------------

Of 2,234 patients who received standard anti-TB treatment during the study period, 397 (17.8%) had peripheral blood eosinophilia during treatment. Of 397 with peripheral blood eosinophilia, the following were excluded: those transferred to another institution before treatment completion (n = 58), those with peripheral blood eosinophilia before starting anti-TB drugs (n = 20), those lost to follow-up (n = 37), and those started on anti-TB drugs in other hospitals (n = 20). Finally, we enrolled 262 patients with peripheral blood eosinophilia and evaluated the clinical and laboratory findings ([Fig. 1](#f1-kjim-2018-063){ref-type="fig"}).

The median patient age was 60 years (IQR, 45 to 73), and 66.8% were men. CADRs were present in 161 (61.5%) of 262 patients with peripheral blood eosinophilia. The median blood eosinophil counts and percentage before start of anti-TB treatment were 110/mm^3^ (IQR, 70 to 200) and 1.9% (IQR, 0.9 to 3.1), respectively; there was no difference in median blood eosinophil counts between patients with and without CADRs (100 vs. 130, *p* = 0.177) or in the median blood eosinophil percentage (1.7 vs. 2.1, *p* = 0.429). Among 161 patients with CADRs, skin rash was the most common presentation, followed by pruritus. The median blood eosinophil counts and percentage at start of CADRs were 400/mm^3^ (IQR, 300 to 500) and 6.2% (IQR, 5.4 to 7.7), respectively. The peak blood eosinophil count and percentage were 465/mm^3^ (IQR, 300 to 650) and 7.7% (IQR, 6.0 to 10.7), respectively ([Table 1](#t1-kjim-2018-063){ref-type="table"}). More than half of the patients (53.1%) developed peripheral blood eosinophilia within 4 weeks after anti-TB treatment ([Fig. 2](#f2-kjim-2018-063){ref-type="fig"}). Ninety-five patients (36.3%) had CADRs associated with eosinophilia within 4 weeks. Patients with peripheral blood eosinophilia within 4 weeks had a higher rate of CADRs than patients with eosinophilia after 4 weeks (68.3% vs. 54.5%, *p* = 0.022).

Factors associated with CADRs and comparison of clinical and laboratory findings according to the severity of CADRs in patients with eosinophilia
-------------------------------------------------------------------------------------------------------------------------------------------------

In multivariate analysis, older age, abnormal liver function, and higher peak blood eosinophil percentage were associated with CADRs ([Table 2](#t2-kjim-2018-063){ref-type="table"}). The initial and peak blood eosinophil counts and eosinophil percentages tended to increase with the degree of clinical severity of CADRs caused by the anti-TB drug (Jonckheere-Terpstra test, *p* \< 0.001) ([Table 3](#t3-kjim-2018-063){ref-type="table"}).

Offending drugs and reasons for discontinuation
-----------------------------------------------

Twenty-seven (10.3%) of 262 patients did not continue anti-TB drugs. The most common reasons for discontinuation were drug rash (44.4%) and drug fever (25.9%), followed by DRESS (25.9%). The most common offending drug was ethambutol, followed by pyrazinamide and rifampin ([Table 4](#t4-kjim-2018-063){ref-type="table"}).

DISCUSSION
==========

In this cohort study, patients with peripheral blood eosinophilia during anti-TB treatment frequently developed CADRs, and the levels of eosinophilia increased according to the severity of the CADRs.

Peripheral blood eosinophilia can be caused by allergic, infectious, and neoplastic disorders. Medications are the most common cause of peripheral blood eosinophilia in developed countries \[[@b15-kjim-2018-063]\]. In our study, a significant number of patients (17.8%) receiving anti-TB drugs showed peripheral blood eosinophilia, and many (61.5%) had cutaneous symptoms. This is consistent with a previous study in which the incidence of peripheral blood eosinophilia among patients receiving outpatient parenteral antibiotics was 25% \[[@b16-kjim-2018-063]\]. However, the incidence of cutaneous symptoms among patients with peripheral blood eosinophilia was higher in our study than in a previous study (61.5% vs. 15%) \[[@b16-kjim-2018-063]\]. Although there was no clear cause that could explain the difference, different drugs and duration of treatment might contribute.

It has been reported that eosinophils could be involved in CADRs, according to in vivo and in vitro studies \[[@b23-kjim-2018-063]-[@b25-kjim-2018-063]\]. Additionally, CADRs associated with peripheral blood eosinophilia have been reported, especially in DRESS syndrome \[[@b1-kjim-2018-063],[@b2-kjim-2018-063],[@b24-kjim-2018-063],[@b26-kjim-2018-063]\]. Yang et al. \[[@b27-kjim-2018-063]\] reported that CADRs in patients with peripheral blood eosinophilia had poor liver function, prolonged use of corticosteroids, and longer hospitalization, which suggested severe disease. In our study, liver function abnormality was associated with CADRs in patients with eosinophilia during anti-TB medication. This finding was consistent with the previous study and suggested that peripheral eosinophilia associated with anti-TB medication might be similar to that with other antibiotic treatments. However, the relationship between peripheral eosinophil counts and severity of CADRs has not been fully studied. Interestingly, the initial and peak blood eosinophil counts and eosinophil percentages tended to increase with clinical severity of CADRs caused by the anti-TB drugs in this study. Therefore, if patients using anti-TB medication develop peripheral eosinophilia and CADRs, increasing peripheral eosinophil counts might be a warning sign of severe CADRs, requiring careful monitoring for progression.

Discontinuation of offending drugs owing to CADRs has been reported in about 4% to 5% of cases \[[@b4-kjim-2018-063],[@b16-kjim-2018-063]\]. In this study, the discontinuation rate was about 10%, which was higher than in previous studies. As the study institution is a tertiary university hospital, more severely ill patients might have been enrolled in this study compared with those in previous studies. All anti-TB drugs are known to have the potential to cause CADRs \[[@b1-kjim-2018-063]\]. In our study, ethambutol was the most common anti-TB drug that caused CADRs, which is in contrast to other studies in which pyrazinamide or isoniazid and rifampin have been reported to be the most common offending drugs \[[@b4-kjim-2018-063],[@b28-kjim-2018-063]\].

This study has several limitations as it is a single-center, retrospective study. First, not all patients with TB and peripheral blood eosinophilia that occurred during treatment were enrolled in this study, and anti-parasite antibody tests that could be used to analyze the causes of peripheral blood eosinophilia were not evaluated. However, enrolling a larger number of patients, as well as excluding patients with peripheral blood eosinophilia before receipt of anti-TB drugs and previous allergy history, could strengthen the findings of this study. Second, this study did not include a control group. Therefore, no comparison was made between patients with and without eosinophilia.

In conclusion, peripheral blood eosinophilia is common during anti-TB treatment, and the majority of those with eosinophilia experienced CADRs. Higher peripheral blood eosinophilia is associated with more severe CADRs.

KEY MESSAGE
===========

1\. Peripheral blood eosinophilia was relatively common (17.8%) in 2,234 patients during anti-tuberculosis treatment, with symptoms including itching and a skin rash.

2\. There was a significant relationship between increased peak eosinophil counts and the severity of cutaneous adverse drug reactions
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###### 

Baseline characteristics of patients with eosinophilia during anti-tuberculosis treatment

  Variable                                                                                      All (n = 262)
  --------------------------------------------------------------------------------------------- -----------------
  Age, yr                                                                                       60 (45--73)
  Male sex                                                                                      175 (66.8)
  Type of TB                                                                                    
   Pulmonary TB                                                                                 162 (61.8)
   Extrapulmonary TB                                                                            100 (38.2)
  Adverse reactions                                                                             
   GI disorder                                                                                  118 (45.0)
   Abnormal liver function                                                                      32 (12.2)
   Abnormal renal function                                                                      10 (3.8)
   CADRs                                                                                        161 (61.5)
    Pruritus only                                                                               76 (47.2)
    Skin rash                                                                                   77 (47.8)
    DRESS                                                                                       7 (4.4)
    SJS/TEN                                                                                     1 (0.6)
   Fever                                                                                        15 (5.7)
  History of previous anti-TB treatment                                                         
   New treatment                                                                                238 (90.8)
   Retreatment                                                                                  24 (9.2)
  Peripheral blood eosinophilia                                                                 
   Eosinophil count before start of anti-TB treatment, /mL                                      110 (70--200)
   Eosinophil percentage before start of anti-TB treatment, % of total white blood cell count   1.9 (0.9--3.1)
   Initial eosinophil count/mL                                                                  400 (300--500)
   Initial eosinophil percentage, % of total white blood cell count                             6.2 (5.4--7.7)
   Peak eosinophil count/mL                                                                     465 (300--650)
   Peak eosinophil percentage, % of total white blood cell count                                7.7 (6.0--10.7)

Values are presented as median (interquartile range) or number (%).

TB, tuberculosis; GI, gastrointestinal; CADR, cutaneous adverse drug reaction; DRESS, drug reaction with eosinophilia and systemic symptom; SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis.

###### 

Factors associated with cutaneous adverse drug reactions in patients with eosinophilia during anti-tuberculosis treatment

  Variable                                                            No CADRs (n = 101)   CADRs (n = 161)   Univariate *p* value   Multivariate           
  ------------------------------------------------------------------- -------------------- ----------------- ---------------------- ---------------------- ----------
  Age, yr                                                             56 (39--71)          63 (46--75)       0.012                  1.016 (1.000--1.032)   0.045
  Male sex                                                            66 (65.3)            109 (67.7)        0.694                                         
  Type of TB                                                                                                 0.367                                         
   Pulmonary TB                                                       59 (58.4)            103 (64.0)                                                      
   Extrapulmonary TB                                                  42 (41.6)            58 (36.0)                                                       
  History of previous anti-TB treatment                                                                      0.742                                         
   New treatment                                                      91 (90.1)            147 (90.7)                                                      
   Retreatment                                                        10 (9.9)             14 (9.3)                                                        
  Abnormal liver function                                             4 (4.0)              28 (17.4)         0.001                  2.828 (1.432--5.582)   0.003
  Abnormal renal function                                             2 (2.0)              8 (4.9)           0.219                                         
  Peripheral blood eosinophil                                                                                                                              
   Base eosinophil count/mL                                           100 (60--200)        130 (75--200)     0.177                                         
   Base eosinophil percentage, % of total white blood cell count      1.7 (0.8--3.0)       2.1 (0.9--3.3)    0.429                                         
   Initial eosinophil count/mL                                        300 (230--465)       400 (300--525)    0.012                                         
   Initial eosinophil percentage, % of total white blood cell count   5.8 (5.3--6.9)       6.7 (5.6--8.4)    \< 0.001                                      
   Peak eosinophil count/mL                                           400 (300--500)       500 (400--775)    \< 0.001                                      
   Peak eosinophil percentage, % of total white blood cell count      6.4 (5.7--8.0)       8.8 (6.7--12.8)   \< 0.001               1.336 (1.189--1.501)   \< 0.001

Values are presented as median (interquartile range) or number (%).

CADR, cutaneous adverse drug reaction; OR, odds ratio; CI, confidence interval; TB, tuberculosis.

###### 

Comparison by severity of cutaneous adverse drug reactions in patients with eosinophilia during anti-tuberculosis treatment

  Variable                                                            No CADRs (n = 101)   Pruritus only (n = 76)   Skin rash (n = 58)   Stop medication (n = 27)   *p* value
  ------------------------------------------------------------------- -------------------- ------------------------ -------------------- -------------------------- -----------
  Age, yr                                                             56 (39--71)          70 (51--77)              58 (40--75)          61 (50--70)                0.008
  Male sex                                                            66 (65.3)            46 (60.5)                45 (77.6)            18 (66.7)                  0.213
  Type of TB                                                                                                                                                        0.759
   Pulmonary TB                                                       59 (58.4)            50 (65.8)                37 (63.8)            16 (59.3)                  
   Extrapulmonary TB                                                  42 (41.6)            26 (34.2)                21 (36.2)            11 (40.7)                  
  History of previous anti-TB treatment                                                                                                                             0.980
   New treatment                                                      91 (90.1)            69 (90.8)                53 (91.4)            25 (92.6)                  
   Retreatment                                                        10 (9.9)             7 (9.2)                  5 (8.6)              2 (7.4)                    
  Peripheral blood eosinophil                                                                                                                                       
   Base eosinophil count/mL                                           100 (60--200)        130 (100--200)           120 (70--200)        200 (60--280)              0.285
   Base eosinophil percentage, % of total white blood cell count      1.7 (0.8--3.0)       2.2 (0.9--3.3)           1.7 (0.8--3.3)       2.0 (0.7--3.3)             0.800
   Initial eosinophil count/mL                                        300 (230--465)       370 (300--445)           400 (300--600)       500 (310--900)             \< 0.001
   Initial eosinophil percentage, % of total white blood cell count   5.8 (5.3--6.9)       6.1 (5.1--7.8)           7.0 (5.7--8.3)       8.0 (6.7--12.0)            \< 0.001
   Peak eosinophil count/mL                                           400 (300--500)       430 (300--600)           500 (400--753)       1,300 (600--2,600)         \< 0.001
   Peak eosinophil percentage, % of total white blood cell count      6.4 (5.7--8.0)       7.3 (6.2----9.8)         9.2 (7.3--12.4)      17.4 (12.0--27.5)          \< 0.001

Values are presented as median (interquartile range) or number (%).

CADR, cutaneous adverse drug reaction; TB, tuberculosis.

###### 

Offending drugs and reasons for discontinuation of anti-TB treatment

  Variable                                  Total (n = 27)
  ----------------------------------------- ----------------
  Reasons for discontinuing anti-TB drugs   
   Drug rash                                12 (44.4)
   Drug fever                               7 (25.9)
   DRESS syndrome                           7 (25.9)
   SJS/TEN                                  1 (3.8)
  Offending drugs                           
   Isoniazid                                5 (16.7)
   Rifampin                                 5 (16.7)
   Ethambutol                               10 (33.3)
   Pyrazinamide                             6 (20.0)
   Unknown                                  4 (13.3)

Values are presented as number (%). There were two offending drugs in three patients (isoniazid and pyrazinamide in one patient, ethambutol and pyrazinamide in two patients).

TB, tuberculosis; DRESS, drug reaction with eosinophilia and systemic symptom; SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis.
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